Abstract
A novel class of agents that block the effects of calcitonin gene‐related peptide (CGRP) may provide a further therapeutic option for people whose migraine has not responded to established treatments or when other preventive treatments are unsuitable due to comorbidities, adverse effects or low adherence. Here the author reviews four monoclonal antibodies that have been licensed or are undergoing regulatory assessment for the prevention of migraine.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
